Waters Corporation (WAT)

Waters Corp. stock experienced a moderate decline of approximately 8% over the past year due to investor caution regarding the BD Biosciences acquisition. The stock fell 12% on February 9, 2026, following the completion of the acquisition due to weaker-than-expected performance of the acquired business. However, the standalone Waters business delivered strong Q4 2025 results, with revenue of $932 million and non-GAAP EPS of $4.53, and provided positive 2026 revenue and EPS guidance. A director, Wei Jiang, purchased 500 shares of the company's stock on March 16, 2026.

Waters Corp. typically experiences increased sales in its fourth quarter due to customer purchasing habits for capital goods as they exhaust their spending budgets by the calendar year-end.

Waters Corp. specializes in analytical instruments and software, including chromatography, mass spectrometry, and thermal analysis, serving industries like life sciences, materials science, and food science. Its products are used for research and development, quality assurance, and laboratory functions. Waters' offerings include LC, MS, and GC systems, sample preparation products, chromatography columns, and software tools. The acquisition of BD's Biosciences and Diagnostic Solutions business has expanded Waters into flow cytometry and clinical microbiology. The company's business segments include instrument systems, chemistry consumables, thermal analysis, and customer support services.

Waters Corp. operates directly in over 35 countries and serves customers in over 100 countries, with key markets in Europe, the Americas, and Asia. Asia accounts for approximately 38% of sales, the Americas roughly 32%, and Europe about 25%. The company has manufacturing facilities in nine U.S. locations and eleven international locations. Waters has a strong presence in China and is targeting expansion in India.

Waters Corp. has maintained a strong brand reputation, particularly in customer satisfaction and service. Its service team was recognized for delivering the highest service satisfaction scores among instrument vendors in the life science tools industry, and the company leads in net promoter scores. CEO Udit Batra's focus on "Commercial Excellence" has increased service-plan attachment and eCommerce adoption. The management team has been lauded for its disciplined capital allocation, demonstrated by the acquisition of Wyatt Technology in 2023.

Waters Corp. is predominantly owned by institutional investors, holding nearly 98% of the shares as of FY2025. Mutual funds account for a substantial portion at around 86.37%. Major institutional shareholders include The Vanguard Group (11.8%), BlackRock, Inc. (8.5%), State Street Corporation (4.7%), and T. Rowe Price Associates (4.2%). Individual board members and officers own about 0.6% of outstanding common stock, with insiders holding under 1% of shares.